{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-024891","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2023-08-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.668675+00:00","generated_at":"2026-06-11T01:59:36.762905+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Monopar receives Nasdaq notice for bid price deficiency; 180 days to regain compliance","bullets":["Nasdaq notified Monopar on Aug 28, 2023 that bid price closed below $1.00 for 30 consecutive days.","Company has 180 calendar days (until Feb 26, 2024) to regain compliance with minimum $1.00 bid price.","To regain compliance, stock must close at $1.00 or more for at least 10 consecutive business days.","If non-compliant by deadline, Monopar may qualify for a second 180-day cure period subject to other listing standards."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-024891","json":"https://secwatch.observer/filing/0001437749-23-024891.json","markdown":"https://secwatch.observer/filing/0001437749-23-024891.md","text":"https://secwatch.observer/filing/0001437749-23-024891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923024891/0001437749-23-024891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923024891/mnpr20230828_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T01:59:36.762905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68cfb10b30274740afd38304dd21f2897cc68daf","claim":"Monopar Therapeutics received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"August 28, 2023, Monopar Therapeutics Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq Capit","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923024891/0001437749-23-024891-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}